Why Women-Run Companies Deserve a Place in Your Portfolio
BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
Zacks Investment Research9/24/2026Neutral
HALO
Halozyme Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$12.93B
P/E Ratio
33.40
EPS
$3.41
Beta
0.88
52W High
$116.85
52W Low
$61.23
50-Day MA
$99.74
200-Day MA
$77.13
Dividend Yield
—
Profit Margin
24.90%
Forward P/E
11.45
PEG Ratio
-2.50
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $1.66B |
| Gross Profit (TTM) | $1.27B |
| EBITDA | $1.05B |
| Operating Margin | 59.80% |
| Return on Equity | 173.70% |
| Return on Assets | 25.50% |
| Revenue/Share (TTM) | $14.15 |
| Book Value | $1.26 |
| Price-to-Book | 88.91 |
| Price-to-Sales (TTM) | 7.77 |
| EV/Revenue | 8.82 |
| EV/EBITDA | 11.80 |
| Quarterly Earnings Growth (YoY) | 42.90% |
| Quarterly Revenue Growth (YoY) | 47.70% |
| Shares Outstanding | $113.50M |
| Float | $112.19M |
| % Insiders | 1.11% |
| % Institutions | 112.14% |
Historical Volatility
HV 10-Day
31.39%
HV 20-Day
25.71%
HV 30-Day
27.94%
HV 60-Day
45.60%
HV Rank
22.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($99.56 target)
2
Strong Buy5
Buy2
HoldLatest News
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. FTNT, ABBNY, EAT and HALO are some such stocks.
Zacks Investment Research9/23/2026Positive
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks Investment Research9/23/2026Positive
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes").
PRNewsWire9/18/2026Neutral
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes").
PRNewsWire9/16/2026Neutral
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Zacks Investment Research9/16/2026Positive
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Seeking Alpha9/16/2026Neutral
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/15/2026Neutral
4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike Fears
Unlock your portfolio value by investing in high earnings yield stocks like Ternium, Halozyme, POSCO and Talos Energy.
Zacks Investment Research9/15/2026Positive
4 Best PEG Value Stocks to Buy Now for Strong Growth & Return
These four PEG value stocks combine discounted valuations with strong growth prospects, offering investors potential opportunities amid market volatility.
Zacks Investment Research9/14/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HALO and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/28/2026